Clinical trial
A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
NCT04632433 is registered in ClinicalTrials.gov with Fondazione Melanoma Onlus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma
- Lead sponsor
- Fondazione Melanoma Onlus
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 10, 2021
- Completion date
- February 1, 2026
- Enrollment
- 25 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.